Stefansson also oversaw deCODE bringing to market clinical tests for polygenic risk of type 2 diabetes, heart attack, prostate cancer, and atrial fibrillation and stroke.  Marketing of these products and deCODEme ceased with the company's financial troubles in 2011, but recent high-profile studies from Massachusetts General Hospital have revived interest in the medical value polygenic risk testing. These tests are using more markers and new algorithms to build upon the risk variants and approach pioneered in Iceland for these same diseases.